RE: Sp30 Apr 2022 22:46
Evening all
Content with yesterdays RNS , & more importantly the forward horizon for all stockholders,
Said it many times as has Vlad , clinical trials is the heavy artillery to propel the stock , however will likely get a nudge north next week ,
Gradual rise back into double figures over next few months would certainly suffice for stockholders, then into clinical trials for the substantial stock return .
Anyhow just my Rum musings ,
Here’s a bag of Hemo market stock numbers
Stock on loan / shorts
100k - very low
Utilization- n/a - no % showing as very little short interest in this stock
Cost to borrow - 15 - high
MCAP - 15.43 million
Average volume - 7.4 million
Shares outstanding- 980 - million
Free float - 839 million
Insiders -
116.64m 11.9 Sandler, Vladislav Founder, CEO 28 Jun 2019
6.33m 0.65 Beeston, Adrian Non-Executive Director 9 Feb 2018
5.6m 0.57 Redmond, Peter Non-Executive Director30 Jan 2020
2.72m 0.28 Wright, Andrew Group Financial Controller 18 May 2021
Stockholders - As of Feb above 2 million
( not showing monthly % changes but can load if required)
HBOS Investment Fund Managers Limited 98.18m
IG Group Holdings Plc, Asset Management Arm 87.11m
Barclays Bank PLC, Wealth and Investment Management Division 54.36m
A J Bell Holdings Limited, Asset Management Arm50.31m
HSBC Global Asset Management (UK) Limited 40.22m
Jarvis Securities plc, Asset Management Arm 20.91m
Pictet Asset Management Limited 19.99m
43North 11.37m
Fidelity International Ltd 6.52m
Close Asset Management Limited 6.39m
Global Prime Partners Ltd, Asset Management Arm4.76m
Merrill Lynch & Co. Inc., Banking Investments 4.27m
Charles Stanley & Co. Ltd, Asset Management Arm 4m
Citigroup Inc.,Banking and Securities Investments3.6m
Joh. Berenberg, Gossler & Co. KG, Asset Management Arm3.57m
Thomas Grant & Co. Ltd., Asset Management Arm 3.33m
Lloyds Banking Group plc 2.99m
UBS Asset Management 2.18m
Equiniti Group Limited, Asset Management Arm 2.04m
Bullet points from RNS - results
.HEMO-CAR-T - strong progress in moving towards human trials
.CBR viral infection treatment - proof of concept achieved and provisional patent application filed
.CDX bi-specific antibody - patents granted and licensing agreement with Lilly
.Move to new facility to enable more cost-effective work & support of clinical trials post year end
.Operating loss of circa £2.7 million (2020: circa £2.2 million); year end cash over £6.8m
.Repayment and replacement of convertible loan facility
If any mistakes blame my Rum consumption
Good luck all
Respect to Ukrainians